Overview
- OpenAI rolled out a GPT‑Rosalind upgrade this week built on GPT‑5.5 that adds agentic coding, richer tool use, and deeper reasoning for medicinal chemistry and genomics.
- The company reported evaluation gains on its proprietary LifeSciBench suite, including MedChemBench and GeneBench, and higher practical lab‑assistance scores on LabWorkBench versus GPT‑5.5.
- OpenAI is not publicly releasing Rosalind and is instead offering a research‑preview and sponsored access to vetted national labs, public‑health partners, and approved developers.
- New plugins and interactive viewers link evidence retrieval, bioinformatics workflows, and biological file formats so approved researchers can move from analysis to executable lab protocols.
- The initiative builds on OpenAI’s prior investments and partnerships with biosecurity startups and is being piloted with high‑security institutions, a strategy meant to speed vaccine and threat‑screening work while limiting dual‑use risk.